CMV is a member of the herpes virus family, but it is not the same as the viruses that cause cold sores or genital herpes.

Approximately 50-80% of adults in the United States have been infected with CMV by the time they reach adulthood, although most have no symptoms.

Also worth reading: What are the crypto IRA tax benefits in 2026 and how does AI analysis improve retirement strategy? · What are the best crypto custodians for SDIRA in 2026? · What is the best Bitcoin ETF for retirement accounts in 2026?

CMV can be transmitted through bodily fluids like saliva, urine, blood, and breast milk, as well as from mother to child during pregnancy or at birth.

Congenital CMV infection, where the virus is passed from mother to baby during pregnancy, is the leading infectious cause of long-term hearing loss and developmental disabilities in children.

People with weakened immune systems, such as those with HIV/AIDS, organ transplant recipients, or cancer patients, are at higher risk for serious CMV disease.

CMV infection can cause a mononucleosis-like illness with symptoms like fever, fatigue, and swollen lymph nodes, but many people have no symptoms at all.

CMV can reactivate and cause disease later in life, especially in individuals with weakened immune systems.

This is because the virus remains dormant in the body after initial infection.

Diagnosis of CMV infection typically involves blood tests to detect the presence of CMV antibodies or the virus itself.

Treatment for CMV infection is usually only necessary for those with severe symptoms or weakened immune systems.

Antiviral medications like ganciclovir or valganciclovir may be used.

Pregnant women can take steps to reduce the risk of CMV infection, such as avoiding contact with young children's saliva and urine and practicing good hand hygiene.

Researchers are exploring the potential link between CMV infection and an increased risk of certain chronic diseases, such as cardiovascular disease and some types of cancer.

The development of a CMV vaccine has been a long-standing challenge, but several promising candidates are currently in clinical trials.

CMV can cause serious complications in newborns, including hearing loss, vision problems, intellectual disabilities, and even life-threatening infections.

Infants born with congenital CMV infection may not show symptoms at birth but can develop complications later in childhood, underscoring the importance of early detection and monitoring.

CMV can be transmitted through blood transfusions, organ transplants, and even sexual contact, highlighting the need for screening and precautions in healthcare settings.

While most healthy individuals clear CMV infections without treatment, the virus can persist and reactivate, potentially causing recurrent symptoms or complications.

Antiviral medications used to treat CMV infections can have significant side effects, making it important for patients to work closely with their healthcare providers to manage the treatment.

Researchers are investigating the use of CMV-specific T cells as a potential immunotherapy approach to enhance the body's natural defenses against the virus.

Early detection and intervention are crucial for managing CMV infections, especially in high-risk groups like newborns and immunocompromised patients.

The global burden of CMV infections is significant, with the virus estimated to affect millions of people worldwide, underscoring the need for continued research and public health efforts to address this common, yet potentially serious, viral infection.